BPL-003
Archives of Psychiatry Research December 29, 2025 Darko Vlahović, D. Vlahovic
BPL-003 is a novel investigational psychedelic compound being developed for the treatment-resistant depression (TRD). Its active ingredient, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), is a serotonergic psychedelic with preferential agonism at 5-HT1A receptors and rapid pharmacokinetics, allowing for a brief, supervised in-clinic administration. Preclinical studies demonstrate that 5-MeO-DMT...
DOI: 10.20471/dec.2025.61.03.09 (opens in new tab)
Serotonergic
Neuroplasticity
Adverse effect
Antidepressant
+4